Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator

Table 1 Patient Demographics and Baseline Characteristics (Safety Population)

Baseline characteristic	Total population (N = 16)
Age, years	39.0 (11.8)
Male, n (%)	16 (100)
Race, n (%)
Asian	1 (6.3)
Black or African American	1 (6.3)
White	14 (87.5)
Weight, kg	82.5 (15.6)
Height, cm	174.9 (7.9)
Body mass index, kg/m²	26.8 (3.5)
Smoking status, n (%)
Former	1 (6.3)
Never	15 (93.8)
Asthma severity per GINA 2006 stages, n (%)
Category I^a	8 (50.0)
Category II^b	8 (50.0)
Duration of asthma, years	25.9 (11.5)
Prebronchodilator % predicted FEV₁	80.8 (9.3)
Bronchial reversibility, %	20.2 (7.9)
Prior medication^c for asthma, n (%)	1 (6.3)

FEV₁ forced expiratory volume in 1 s, GINA Global Initiative for Asthma
Data are mean (standard deviation) unless otherwise specified
^aFEV₁ ≥ 80% of predicted value (mild persistent)
^bFEV₁ ≥ 60% of predicted value and < 80% of predicted value
^cWithin 15 days prior to providing informed consent until the first administration of study medication

ISSN: 1465-993X